Thromboxane A2 Receptor Antagonist
Oral Ifetroban for Scleroderma
Recruiting0 awardsPhase 2
Tucson, Arizona
This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Prostacyclin Analogue
Treprostinil for Pulmonary Arterial Hypertension
Recruiting3 awardsPhase 4
Omaha, Nebraska
This trial will study the effects of a medication called treprostinil on people with pulmonary arterial hypertension. The goal is to see if the medication can lower the pressure in the arteries of the lungs and improve the function of the right ventricle of the heart.
Prostacyclin Analogue
Treprostinil Palmitil for Pulmonary Arterial Hypertension
Recruiting0 awardsPhase 2
West Hollywood, California
This trial is testing an inhalable medicine called TPIP to see if it can help people with high blood pressure in their lungs by making it easier for blood to flow through their lung arteries.
Popular Filters
Trials for PAH Patients
Biguanides
Metformin + mHealth for Pulmonary Arterial Hypertension
Recruiting0 awardsPhase 2
Nashville, Tennessee
This trial is testing two interventions to see if they can improve insulin resistance in people with pulmonary artery hypertension. The primary endpoint is a 10% improvement in the distance the person can walk in six minutes, or an improvement in the person's functional class according to the World Health Organization.
Prostacyclin Receptor Agonist
Selexipag for Pulmonary Arterial Hypertension
Recruiting1 awardPhase 2
Aurora, Colorado
This trial aims to find the right dose of Selexipag for children with Pulmonary Arterial Hypertension (PAH). Selexipag helps by relaxing lung blood vessels, lowering blood pressure, and improving blood flow. The goal is to ensure the treatment is safe and effective for younger patients.
Vascular Function in Pulmonary Arterial Hypertension
Recruiting2 awardsPhase 1
Salt Lake City, Utah
This trial is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease.
Trials for PH Patients
Device
Aria CV System for Pulmonary Arterial Hypertension
Recruiting1 award10 criteria
Boston, Massachusetts
This trial is testing a new device called the Aria CV PH System, which helps manage high blood pressure in the lungs and supports heart function. It is aimed at patients with pulmonary hypertension and related heart issues. The study will check if the device is safe and effective over a period of several months to a few years.
Neuromodulation
Neuromodulation for Pulmonary Arterial Hypertension
Recruiting0 awardsPhase 1 & 2
Oklahoma City, Oklahoma
This trial aims to study the effects of low-level tragal stimulation in patients with pulmonary hypertension. Patients will undergo stimulation for 1 hour daily for 4 weeks. Tests will be conducted before and after
Prostacyclin Analog
L606 Inhalation Suspension for Pulmonary Arterial Hypertension
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial tests a new medication called L606 in patients with specific types of lung disease. It aims to see if L606 is safe, helps patients breathe better, and improves their quality of life compared to an existing treatment called Tyvaso. LIQ861 is a novel dry-powder formulation of treprostinil, similar to the inhaled, nebulized treprostinil (Tyvaso®).
Prostacyclin Receptor Agonist
Ralinepag for Pulmonary Arterial Hypertension
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing ralinepag, a medication being developed for the treatment of pulmonary arterial hypertension (PAH). It aims to see if adding ralinepag to their usual treatments can improve their condition. The medication works by relaxing and opening up the blood vessels in the lungs, which can lower the pressure and improve blood flow.
Phase 3 Trials
Endothelin Receptor Antagonist
Macitentan for Pulmonary Hypertension
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing macitentan, a drug that helps lower lung blood pressure, in children with pulmonary arterial hypertension. Macitentan has shown significant effectiveness in improving the condition of patients with pulmonary arterial hypertension.
Endothelin Receptor Antagonist
High-Dose Macitentan for PAH
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial is testing if a higher dose of macitentan can better help patients with pulmonary arterial hypertension by improving blood flow in their lungs. Macitentan has shown promise in helping patients by slowing down the disease and improving their health.
Prostacyclin Analog
L606 Inhalation Suspension for Pulmonary Arterial Hypertension
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial tests a new medication called L606 in patients with specific types of lung disease. It aims to see if L606 is safe, helps patients breathe better, and improves their quality of life compared to an existing treatment called Tyvaso. LIQ861 is a novel dry-powder formulation of treprostinil, similar to the inhaled, nebulized treprostinil (Tyvaso®).
Trials With No Placebo
Prostacyclin Receptor Agonist
Selexipag for Pulmonary Arterial Hypertension
Recruiting1 awardPhase 2
Aurora, Colorado
This trial aims to find the right dose of Selexipag for children with Pulmonary Arterial Hypertension (PAH). Selexipag helps by relaxing lung blood vessels, lowering blood pressure, and improving blood flow. The goal is to ensure the treatment is safe and effective for younger patients.
Vascular Function in Pulmonary Arterial Hypertension
Recruiting2 awardsPhase 1
Salt Lake City, Utah
This trial is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease.
Endothelin Receptor Antagonist
Macitentan for Pulmonary Hypertension
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing macitentan, a drug that helps lower lung blood pressure, in children with pulmonary arterial hypertension. Macitentan has shown significant effectiveness in improving the condition of patients with pulmonary arterial hypertension.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.